CLINICAL_TRIALS
trial_result
· 2011-10-28
Clinical Trial Update: Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis [Phase 3]
Summary
Phase 3 trial evaluating the efficacy and safety of 35 mg of risedronate given once weekly in men with osteoporosis; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Warner Chilcott | Conditions: Other Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2011-10-28